Luo Yaping: Clinical Trials

4 trials sponsored by Luo Yaping, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting, 1 not yet recruiting. 4 Not applicable.

By phase and status

PhaseTrialsStatus
Not applicable4Recruiting 3, Not yet recruiting 1

Follow Luo Yaping: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Study on the Effectiveness of [68Ga]Ga-HBED-CC-DiAsp PET/CT in Calculating GFR and Predicting Residual Renal Function After Partial Nephrectomy
GFR will be measured using three methods at two weeks before surgery and four ± one week after surgery, GFR will be measured using three methods: [68Ga]Ga-HBED-CC-DiAsp PET/CT, the Gates method, and the dual plasma sampling method with 99mTc-DTPA. - Kidney Neoplasms / Surgery, Glomerular Filtration Rate
Not applicableNot yet recruitingLuo Yaping402025-07-012025-05-15
A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD
68Ga-FAPI PET / CT - IgG4-Related Diseases
Not applicableRecruitingLuo Yaping462025-05-102025-08-05
Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC
68Ga-DOTA-CCK-FS PET/CT - Medullary Thyroid Carcinoma
Not applicableRecruitingLuo Yaping302025-05-102025-08-24
Research on the Application of 99mTc-TCR-FAPI SPECT Imaging in Rheumatoid Arthritis
68Ga-FAPI PET/CT and 99mTc-CTR-FAPI SPECT - Rheumatoid Arthritis (RA)
Not applicableRecruitingLuo Yaping202025-05-102025-08-24

Conditions studied

Arthritis, Rheumatoid (1)  ·  Carcinoma, Medullary (1)  ·  Immunoglobulin G4-Related Disease (1)  ·  Kidney Neoplasms (1)

Countries

China (4)

Results publications

PMID 23658207, PMID 25678493, PMID 27553470, PMID 31869735, PMID 38006535, PMID 6374072